Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Surperformance© rating of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More about the company
Financials (€)
Sales 2014 17,1 M
EBIT 2014 -1,82 M
Net income 2014 -1,78 M
Finance 2014 26,0 M
Yield 2014 -
Sales 2015 5,02 M
EBIT 2015 -15,0 M
Net income 2015 -15,8 M
Debt 2015 2,00 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 9,51x
EV / Sales 2015 38,0x
Capitalization 189 M
More Financials
Latest news on BIOALLIANCE PHARMA SA
5d ago ONXEO : BPIFrance Grants Onxeo EUR1.25 Million
10/10 ONXEO : reaches second milestone of BPIFrance grant dedicated to Livatag® develo..
09/28 ONXEO : Participates in InvestorDagen 2014
09/25 ONXEO : receives “Silver Governance” – Corporate Governance-pr..
09/24 ONXEO : announces participation in the Midcap Event On October 2nd and 3rd, 2014..
09/24 ONXEO : announces participation in the Midcap Event On October 2nd and 3rd, 2014..
09/24 ONXEO : Participates in InvestorDagen 2014
09/24 ONXEO : Participates at InvestorDagen 2014
09/19 ONXEO : attends InvestorDagen 2014, the largest Danish private investor event / ..
09/10 ONXEO : Gets U.S. Patent for Beleodaq
09/03 ONXEO : Receives U.S. Patent for Beleodaq
08/28 ONXEO : strengthens Beleodaq® patent protection in the U.S. until 2027 – O..
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF